Multiple cellular electrophysiological effects of azimilide in canine cardiac preparations.

Department of Cardiology, Karolina Hospital, H-9200, Mosonmagyaróvár, Hungary.
European Journal of Pharmacology (Impact Factor: 2.68). 07/2003; 470(3):163-70. DOI: 10.1016/S0014-2999(03)01792-8
Source: PubMed

ABSTRACT The cellular electrophysiological effect of azimilide (0.1-30 microM) was analyzed in canine ventricular preparations by applying the standard microelectrode and patch-clamp techniques at 37 degrees C. In papillary muscle, the drug prolonged the action potential duration (APD) in a concentration-dependent manner at a cycle length (CL) of 1000 ms. In Purkinje fibers, at the same CL, the concentration-dependent lengthening of the APD was observed in the presence of up to 3 microM azimilide (at 3.0 microM: 24.1+/-4.2%, n=9); at higher drug concentration, no further APD prolongation was observed. Azimilide lengthened APD in a reverse frequency-dependent manner in papillary muscle and Purkinje fibers alike. Azimilide (10 microM) caused a rate-dependent depression in the maximal upstroke velocity of the action potential (V(max)) in papillary muscle. The time and rate constants of the offset and onset kinetics of this V(max) block were 1754+/-267 ms (n=6) and 5.1+/-0.4 beats (n=6), respectively. Azimilide did not prevent the APD shortening effect of 10 microM pinacidil in papillary muscle, suggesting that the drug does not influence the ATP-sensitive K(+) current. Azimilide inhibited the rapid (I(Kr)) and slow component (I(Ks)) of the delayed rectifier K(+) current and the L-type Ca(2+) current (I(Ca)). The estimated EC(50) value of the drug was 0.59 microM for I(Ks), 0.39 microM for I(Kr) and 7.5 microM for I(Ca). The transient outward (I(to)) and the inward rectifier (I(k1)) K(+) currents were not influenced by the drug. It is concluded that the site of action of azimilide is multiple, it inhibits not only K(+) (I(Kr), I(Ks)) currents but, in higher concentrations, it also exerts calcium- and use-dependent sodium channel block.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and PurposeThis study was designed to examine the antiarrhythmic efficacy and the underlying mechanisms of the benzyl-furoquinoline vasodilator CIJ-3-2F in rat cardiac preparations.Experimental ApproachConduction electrograms and left ventricular (LV) pressure were determined in Langendorff-perfused hearts. Action potentials were assessed with microelectrode technique, calcium transients by fura-2 fluorescence and ionic currents by whole-cell patch-clamp techniques.Key ResultsIn isolated hearts, CIJ-3-2F prolonged sinus cycle length, QT interval, Wenckebach cycle length, atrio-His bundle and His bundle-ventricular conduction intervals, refractory periods in atrium, AV node, His-Purkinje system, and ventricle, and also increased LV pressure. CIJ-3-2F reduced the incidences of both ischaemic and reperfusion-induced ventricular arrhythmias and prevented the induction of atrial tachyarrhythmias. In both atrial and papillary muscles, CIJ-3-2F decreased upstroke velocity and prolonged duration of the action potential. In ventricular myocytes, CIJ-3-2F moderately increased the amplitude of [Ca2+]i transient and cell shortening. CIJ-3-2F inhibited the transient outward K+ current (Ito) (IC50 = 4.4 mM) with an acceleration of its inactivation, a slowed rate of recovery from inactivation, and use-dependency. CIJ-3-2F also suppressed the steady-state outward K+ current (Iss, IC50 = 3.6 mM, maximum inhibition = 65.7%) and both the inward Na+ current (INa, IC50 = 2.8 mM) and L-type Ca2+ current (ICa,L, IC50 = 4.9 mM, maximum inhibition = 69.4%).Conclusions and ImplicationsCIJ-3-2F blocks Na+ and Ito channels, and also blocks Ca2+ and Iss channels to some extent. These effects lead to a modification of cardiac electromechanical function and are likely to underlie its antiarrhythmic properties.
    British Journal of Pharmacology 05/2014; DOI:10.1111/bph.12752 · 4.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atrial fibrillation (AF) is the most common cardiac arrhythmia, contributing to increased morbidity and reduced survival through its associations with stroke and heart failure. AF contributes to a four- to fivefold increase in the risk of stroke in the general population and is responsible for 10-15 % of all ischemic strokes. Diagnosis and treatment of AF require considerable health care resources. Current therapies to restore sinus rhythm in AF are suboptimal and are limited either by their pro-arrhythmic effects or by their procedure-related complications. These limitations have necessitated identification of newer therapeutic targets to expand the treatment options. There has been a considerable amount of research interest in investigating the mechanisms of initiation and propagation of AF. Despite extensive research focused on the pathogenesis of AF, a thorough understanding of various pathways mediating initiation and propagation of AF still remains limited. Research efforts focused on the identification of these pathways and molecular mediators have generated a great degree of interest for developing more targeted therapies. This review discusses the potential therapeutic targets and the results from experimental and clinical research investigating these targets.
    American Journal of Cardiovascular Drugs 08/2014; 14(6). DOI:10.1007/s40256-014-0085-0 · 2.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atrial fibrillation (AF) is the most common arrhythmia in clinical practice that is associated with a wide range wide of cardiac and extra-cardiac complications and thereby significantly contributes to morbidity and mortality. Present therapeutic approaches to AF have major limitations which have inspired substantial efforts aimed at improving our understanding of the underlying mechanisms, with the premise that improved knowledge will lead to innovative and improved therapeutic approaches. Our understanding of AF pathophysiology has significantly advanced over the past 10 to 15 years through an increased awareness of the role of “atrial remodeling”. Any persistent change in atrial structure or function constitutes atrial remodeling. Atrial remodeling has the potential to increase the likelihood of ectopic or reentrant activity through several putative mechanisms. The present paper reviews the major advances with respect to electrical, structural and contractile remodeling associated with AF, focusing on the underlying pathophysiological and molecular basis of their occurrence. Special attention is paid to novel strategies and targets with therapeutic significance for this frequent pathology.
    Treatment Strategies in Cardiology, Edited by Laura Hajba, 11/2011: chapter Novel pharmacological strategies for antiarrhythmic therapy in atrial fibrillation: pages 50-55; Publisher Cambridge Research Centre.

Full-text (2 Sources)

Available from
May 27, 2014